These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34682890)

  • 21. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
    Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
    Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study.
    Kato T; Nagahara A; Kawamura N; Nakata W; Soda T; Matsuzaki K; Hatano K; Kawashima A; Ujike T; Imamura R; Nishimura K; Takada S; Tsujihata M; Yamaguchi S; Takao T; Nishimura K; Nonomura N; Uemura M
    Int J Clin Oncol; 2021 May; 26(5):954-961. PubMed ID: 33471290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.
    Sattar J; Kartolo A; Hopman WM; Lakoff JM; Baetz T
    J Geriatr Oncol; 2019 May; 10(3):411-414. PubMed ID: 30104155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution.
    Kleef R; Nagy R; Baierl A; Bacher V; Bojar H; McKee DL; Moss R; Thoennissen NH; Szász M; Bakacs T
    Cancer Immunol Immunother; 2021 May; 70(5):1393-1403. PubMed ID: 33151369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study.
    Tanaka T; Hatakeyama S; Numakura K; Kido K; Noro D; Oikawa M; Hosogoe S; Tokui N; Yamamoto H; Narita S; Ito H; Yoneyama T; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
    Int J Urol; 2020 Dec; 27(12):1095-1100. PubMed ID: 32893401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.
    Takada R; Fujiwara M; Maki M; Nomura N; Kono S; Fujita A; Masumoto H; Takahashi Y; Hasegawa Y; Tamura K
    J Pharm Health Care Sci; 2024 May; 10(1):26. PubMed ID: 38822426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
    Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma.
    Kobayashi T; Nagata M; Ikehata Y; Nagashima Y; Nagaya N; Lu Y; Horie S
    Curr Issues Mol Biol; 2023 Nov; 45(11):8939-8949. PubMed ID: 37998738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma.
    Kobayashi K; Iikura Y; Hiraide M; Yokokawa T; Aoyama T; Shikibu S; Hashimoto K; Suzuki K; Sato H; Sugiyama E; Tajima M; Hama T
    In Vivo; 2020; 34(5):2647-2652. PubMed ID: 32871795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study.
    Fink M; Vittrup AS; Bastholt L; Svane IM; Donia M; Luczak AA; Ruhlmann CH; Guldbrandt LM; Koehler UH; Winther ML; Ellebaek E; Haslund CA; Schmidt H
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.